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Abstract: Stereotactic body radiotherapy is an emerging treatment
option for peripheral non-small cell lung cancer in medically inop-
erable patients. With high dose per fraction radiotherapy, late side
effects are of possible concern. In our initial cohort of 42 patients
treated with 54 to 60 Gy in three fractions, nine patients have rib
fracture. The median dose to rib fracture sites was 46 to 50 Gy,
depending on the method of dose calculation. We describe a typical
case of poststereotactic radiotherapy rib fracture and present dosi-
metric analysis of patients with rib fracture.
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An 85-year-old man presented with a peripheral noduleseen incidentally on chest radiograph ordered during
work up of cardiac chest pain. Computed tomography (CT)
imaging revealed a 2.3-cm right upper lobe, spiculated mass
and multiple thoracic lymph nodes measuring up to 1.0 cm in
maximum diameter. A CT-guided biopsy of the mass was
consistent with non-small cell lung cancer (NSCLC). In
addition, abdomen, brain, and bone imaging revealed no
evidence of distant metastatic disease. Whole body fluorode-
oxyglucose-positron emission tomography-CT imaging re-
vealed abnormal metabolic activity in the primary mass (SUV
7.5) and equivocal fluorodeoxyglucose uptake in the medias-
tinal nodes. Because of cardiac comorbidity, mediastinoscopy
was not performed, and his tumor, clinically stage Ia
(cT1N0M0), was deemed inoperable because of his medical
condition. He was referred for consideration of radiotherapy.
He was eligible for stereotactic body radiation therapy
(SBRT) and was treated on a research ethics board-approved
protocol, with a dose of 60 Gray (Gy) in three fractions,
prescribed to an 87% isodose line covering the planning
target volume. Figure 1 shows the radiation isodose lines on
a coronal slice reconstructed from the planning CT scan.
Planning target volumes were constructed with patient-spe-
cific asymmetric margins using four-dimensional CT. Treat-
ment was completed without complication.
The patient remained well until 16 months postra-
diation therapy, when he developed pleuritic right-sided
chest pain, which resolved with 1 month of over-the-
counter analgesics. CT thorax showed ill margination of
the outer cortex of the right fourth antero-lateral rib with
associated chest wall thickening and adjacent increased
lung parenchymal opacity (Figure 2). The radiologic dif-
ferential diagnosis of these findings included rib osteone-
crosis and progression of disease to involve the chest wall.
During subsequent follow-up, a CT scan at 29 months
postradiation therapy showed increased peripheral sub-
pleural consolidation and adjacent rib fracture (Figure 3).
All of the radiographic changes occurred in the region of
high-radiation dose and, with control of primary mass,
treatment-induced changes were favored over disease re-
currence. Positron emission tomography scan was not
performed. The patient’s radiographic changes were fol-
lowed using interval-CT imaging. At last follow-up, he
was clinically and radiologically disease free at 42 months
posttreatment.
DISCUSSION
Despite the increasing popularity of SBRT, experience
with extremely hypofractionated, high-dose radiotherapy reg-
imens and their posttreatment radiologic findings and clinical
toxicity remains limited. At our institution, 42 medically
inoperable patients with peripheral early-stage NSCLC were
treated with 54 to 60 Gy in three fractions before December
2007 in a prospective phase II study. In a subsequent follow-
up, nine of these patients had developed a total of 15 ipsilat-
eral rib fractures, occurring at a median of 17 months follow-up.
Two fractures were asymptomatic and detected radiologically.
Chest wall pain was observed in 11 patients, seven of whom
had fractures. Three patients developed chest wall pain that
initially did not show imaging evidence of fracture but weeks
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FIGURE 1. Isodose distribution
showing the 20 Gray (Gy), 40 Gy,
and 60 Gy isodose lines on a coro-
nal computed tomography (CT)
slice. Heterogeneity correction was
not used for dose calculation. Por-
tions of the rib, chest wall, neuro-
vascular bundle, pleura, and pul-
monary parenchyma receive doses
in excess of 40 Gy in three frac-
tions.
FIGURE 2. Follow-up computed
tomography (CT) (bone window-
ing) demonstrating changes at 16
months postradiotherapy including
cortical thinning (arrow), sugges-
tive of osteonecrosis, and fibrosis of
pulmonary parenchyma, pleura,
and chest wall.
FIGURE 3. Progression to fracture
(arrow) and further progression of
parenchymal pulmonary fibrosis 29
months postradiation therapy (RT).
FIGURE 4. Actuarial proportion of patients free
of fracture as a function of time since treatment.
The exes mark patient deaths, tick marks show
censored patients (last follow-up), and dashed
lines show 95% confidence interval.
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to months later did evolve to include radiologically demon-
strable fracture. All patients with fracture had tumors within
2 cm of the chest wall.
Based on the radiotherapy treatment plans, the sites of
rib fracture received a median radiation dose of 46.4 Gy
(range, 16.5–74.2), calculated without tissue heterogeneity
correction. The median standard deviation in this dose was
7.6 Gy, indicating steep radiation dose gradients at fracture
sites. However, higher or lower doses than planned may
actually have been delivered to the rib fracture sites as a result
of our practice of image guiding the radiation treatment to the
tumor itself (as opposed to neighboring soft tissue or bony
structures) and variation in patient positions among fractions.
Two patients with asymptomatic fractures received maximum
doses of 47.5 and 29.1 Gy (corrected for tissue heterogeneity,
Pinnacle ADAC v 7.6c, Philips Radiation Oncology Systems,
Milpitas, CA) to the fracture site. Six patients with symptom-
atic fracture had transient pain or pain that was manageable
with the medications received at a maximum of 33.0, 39.4,
49.8, 52.7, 56.1, and 67.7 Gy to the fracture site(s). One
patient who developed a fracture with chronic, neuropathic
pain incompletely relieved by medications received 76.4 Gy
to the fracture site. With the tissue inhomogeneity correc-
tions, the median dose delivered to sites of fracture (including
each fractured rib in patients who experienced multiple rib
fractures) was 50.1 Gy (range, 17.1–76.4).
Our experience suggests that rib fracture, pulmonary or
chest wall fibrosis, and chest wall pain can be observed after
SBRT for peripheral NSCLC and may occur commonly in
patients with tumors adjacent to the chest wall. The patho-
genesis of the different forms of chest wall pain is uncertain.
Of note, chronic chest wall pain is observed in approximately
30% of lung cancer patients treated using thoracotomy 4 to 5
years after resection.1
As patient follow-up matures, information relevant to
predicting the likelihood of longer-term chest wall side ef-
fects will become available from our population of patients as
well as those treated at other institutions and with other
hypofractionated regimens. Nguyen et al.2 recently reviewed
the complications of SBRT and included crude rates from
seven studies that observed a total of 16 fractures, with
fracture rates varying from 1.5 to 5%. However, in studies
large enough to examine subgroups of patients who received
high doses to rib or chest wall, fracture rates are considerably
higher. Dunlap et al.3 reported a steep dose-response relation-
ship between dose to volume of chest wall and fracture rate,
with fracture rates as high as 63% for patients with more than
120 mL of chest wall receiving above 30 Gy. Pettersson et
al.4 found a fracture rate of 37% for patients when a volume
of chest wall greater than 2 mL received in excess of 40 Gy.
Dose prescription has been variable in SBRT studies, and
length of follow-up is generally short. Because hypofraction-
ated radiation can be associated with complications occurring
more than 2 years after treatment, the true fracture rate within
our population and the rate from other centers are uncertain
but will certainly be higher than the crude rates quoted from
studies with short follow-up. Kaplan-Meier fracture-free pro-
portion for our study population is shown in Figure 4. Based
on these observations, our current practice is to consider
reducing the total dose to tumor and maximum dose to chest
wall; increasing the number of noncoplanar beams; increas-
ing the number of fractions for stereotactic treatment of periph-
eral lesions where chest wall and/or rib is/are within the high-
dose region, recognizing that there is uncertainty in both the
complication risk and the control probability with SBRT. The
informed patient consent process in our ongoing phase II study
of stereotactic lung radiotherapy includes a discussion of the
potential for fibrosis, chest wall pain, and fracture.
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